Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 17/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15142447 | 0.87 | CYP11B1 (0.48) | PLA2G7PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL29043678 | 0.84 | MAOB (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30553754 | 0.84 | MAOB (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL14999399 | 0.83 | PLA2G7 (0.53) | PLA2G7 | |
| SCHEMBL9931919 | 0.83 | PLA2G7 (0.53) | PLA2G7 | |
| SCHEMBL22573246 | 0.80 | MAOB (0.45) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL14999401 | 0.79 | CYP11B1 (0.54) | PLA2G7 | |
| SCHEMBL21490294 | 0.78 | MAOB (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30368255 | 0.78 | MAOB (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2634173 | 0.77 | PLA2G7 (0.45) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | PLA2G7 875/4885PRKAB2 4737/4885PRKAG1 4795/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | PLA2G7 975/4885PRKAB2 4705/4885PRKAG1 4790/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | PLA2G7 875/4885PRKAB2 4737/4885PRKAG1 4795/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | PLA2G7 975/4885PRKAB2 4705/4885PRKAG1 4790/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | PLA2G7 975/4885PRKAB2 4705/4885PRKAG1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.